Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival In Advanced Colorectal Cancer At The 2023 ESMO World Congress On Gastrointestinal Cancer
Portfolio Pulse from Happy Mohamed
Agenus (NASDAQ:AGEN) has reported promising data from its Phase 1b trial on the botensilimab and balstilimab combination at the 2023 ESMO World Congress on Gastrointestinal Cancer. The data shows substantial survival benefits for patients with non-MSI-H metastatic colorectal cancer previously resistant to chemotherapy and/or immunotherapy. Agenus is planning to submit its first Biologics License Application to the FDA for patients with non-MSI-H metastatic colorectal cancer.
June 30, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agenus' promising data from its Phase 1b trial on the botensilimab and balstilimab combination could potentially boost its stock price in the short term. The company's plan to submit its first Biologics License Application to the FDA could also positively impact its stock.
The promising data from Agenus' Phase 1b trial indicates potential success in the company's cancer treatment research, which could attract more investors and boost its stock price. Additionally, the company's plan to submit its first Biologics License Application to the FDA signifies progress in its product development, which could also positively impact its stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100